Alkem Laboratories Ltd

Alkem Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alkem Laboratories Ltd

₹ 3,364 -0.49%
02 Jun - close price
alkemlabs.com BSE: 539523 NSE : ALKEM
About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Key Points

Leading Pharmaceutical company[1] Alkem is the fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022.
It has established its leadership position in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments.

Website BSE NSE
  • Market Cap ₹ 40,219 Cr.
  • Current Price ₹ 3,364
  • High / Low ₹ 3,625 / 2,835
  • Stock P/E 37.9
  • Book Value ₹ 757
  • Dividend Yield 0.74 %
  • ROCE 13.9 %
  • ROE 12.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 43.7%

Cons

  • Promoter holding has decreased over last 3 years: -8.72%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
2,049 1,992 2,363 2,318 2,192 2,731 2,800 2,619 2,484 2,576 3,079 3,041 2,903
1,746 1,470 1,762 1,789 1,901 2,138 2,176 2,121 2,147 2,373 2,625 2,442 2,549
Operating Profit 303 522 600 529 291 593 624 498 337 203 454 599 353
OPM % 15% 26% 25% 23% 13% 22% 22% 19% 14% 8% 15% 20% 12%
27 55 36 96 46 47 42 54 6 51 51 45 -34
Interest 14 17 18 13 11 13 12 11 17 26 25 27 29
Depreciation 81 67 70 69 69 71 73 77 83 76 77 78 78
Profit before tax 235 493 548 543 258 556 582 464 243 152 402 539 212
Tax % 19% 14% 12% 15% 3% 14% 4% -15% 55% 13% 14% 15% 68%
Net Profit 192 423 482 464 249 480 559 533 108 131 348 460 68
EPS in Rs 15.79 35.30 39.48 37.72 20.07 39.15 45.52 43.96 9.00 10.68 27.67 38.03 5.94
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
2,011 2,485 3,113 3,674 4,905 5,688 6,401 7,357 8,344 8,865 10,634 11,599
1,645 2,123 2,700 3,248 4,038 4,687 5,392 6,237 6,868 6,920 8,580 9,990
Operating Profit 366 362 413 427 866 1,001 1,009 1,120 1,476 1,945 2,054 1,609
OPM % 18% 15% 13% 12% 18% 18% 16% 15% 18% 22% 19% 14%
154 167 162 176 227 110 115 82 102 230 146 113
Interest 58 88 93 81 71 45 55 55 65 59 52 107
Depreciation 29 40 52 71 93 101 143 193 253 275 304 310
Profit before tax 433 402 430 451 928 965 926 955 1,260 1,842 1,844 1,305
Tax % 6% 4% -1% 13% 19% 6% 31% 19% 9% 12% 9% 23%
Net Profit 407 384 435 392 752 905 638 774 1,149 1,618 1,680 1,007
EPS in Rs 340.02 321.01 364.10 32.75 62.02 74.61 52.77 63.61 94.26 132.57 137.63 82.31
Dividend Payout % 6% 6% 5% 12% 20% 20% 25% 25% 27% 23% 25% 84%
Compounded Sales Growth
10 Years: 17%
5 Years: 13%
3 Years: 12%
TTM: 9%
Compounded Profit Growth
10 Years: 11%
5 Years: 11%
3 Years: -2%
TTM: -36%
Stock Price CAGR
10 Years: %
5 Years: 12%
3 Years: 11%
1 Year: 8%
Return on Equity
10 Years: 18%
5 Years: 18%
3 Years: 18%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
12 12 12 24 24 24 24 24 24 24 24 24
Reserves 1,802 2,160 2,567 2,975 3,668 4,444 4,840 5,415 6,137 7,353 8,614 9,021
1,007 1,552 1,128 1,306 658 659 998 944 1,616 1,792 2,668 1,492
644 547 604 986 1,184 1,440 1,803 1,824 2,169 2,351 2,763 3,219
Total Liabilities 3,466 4,271 4,311 5,291 5,534 6,568 7,664 8,208 9,946 11,519 14,069 13,757
919 1,072 1,170 1,374 1,450 1,797 2,284 2,530 2,908 2,793 2,902 2,696
CWIP 0 0 0 111 172 299 381 493 363 393 339 310
Investments 323 478 588 481 509 553 444 324 261 333 371 622
2,224 2,721 2,553 3,325 3,403 3,918 4,555 4,861 6,413 8,000 10,457 10,129
Total Assets 3,466 4,271 4,311 5,291 5,534 6,568 7,664 8,208 9,946 11,519 14,069 13,757

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
159 78 290 325 726 471 266 780 585 1,265 1,111 1,682
-246 -403 353 -235 205 -294 -351 -318 -737 -995 -1,433 113
-11 356 -600 -52 -927 -138 85 -379 79 -272 380 -1,761
Net Cash Flow -98 31 44 39 3 40 0 82 -73 -2 58 35

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 45 47 43 52 42 46 62 62 72 66 65 67
Inventory Days 168 191 163 169 169 198 221 186 198 241 262 194
Days Payable 121 99 81 101 108 122 147 119 104 112 102 87
Cash Conversion Cycle 92 139 126 121 103 122 135 129 167 196 225 174
Working Capital Days 63 96 74 60 48 65 84 88 109 117 120 117
ROCE % 19% 15% 14% 12% 23% 21% 18% 17% 19% 22% 19% 14%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
62.43 62.43 62.43 60.16 58.84 58.84 57.13 57.13 57.14 57.16 57.16 57.16
3.49 3.92 4.08 4.42 4.50 5.33 5.40 5.41 5.67 4.46 4.41 4.44
12.03 12.89 12.96 13.20 14.49 13.99 13.94 14.14 14.10 15.73 16.44 16.69
0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
21.80 20.76 20.53 22.22 22.17 21.84 23.53 23.32 23.09 22.65 21.99 21.69

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls